Mark Erlander, Cardiff Oncology CEO

Cardiff drops its prostate can­cer pro­gram, send­ing shares in­to a tail­spin

Cardiff On­col­o­gy is join­ing the league of com­pa­nies that have de­cid­ed to scrap one of its pro­gram, lead­ing the com­pa­ny’s stock to take a nose dive on Tues­day.

The com­pa­ny an­nounced that it will no longer fund its clin­i­cal tri­als for prostate can­cer and in­stead will fo­cus its ef­forts on pan­cre­at­ic and metasta­t­ic col­orec­tal can­cer.

The com­pa­ny is test­ing its lead can­di­date, on­va­nsert­ib, a PLK1 in­hibitor, along with the stan­dard of care in a va­ri­ety of in­di­ca­tions.

“Fol­low­ing a strate­gic re­view of its clin­i­cal da­ta in metasta­t­ic cas­trate-re­sis­tant prostate can­cer (mCR­PC), as well as the cur­rent and pro­ject­ed ther­a­peu­tic land­scape in this in­di­ca­tion, the com­pa­ny has de­cid­ed it will not in­de­pen­dent­ly fund any fu­ture clin­i­cal ac­tiv­i­ties in mCR­PC,” the com­pa­ny said in a press state­ment.

In Feb­ru­ary of 2021, the com­pa­ny pre­sent­ed Phase II da­ta on the mCR­PC Tri­al show­ing a two-fold in­crease in ef­fi­ca­cy with on­va­nsert­ib when the num­ber of days of treat­ment with the drug was in­creased from five to 14 in a 21-day cy­cle.

Next up, the com­pa­ny is plan­ning a ran­dom­ized Phase II tri­al to eval­u­ate the safe­ty and ef­fi­ca­cy of on­va­nsert­ib in com­bi­na­tion with stan­dard-of-care, which is FOLFIRI/be­va­cizum­ab, in sec­ond-line KRAS/NRAS-mu­tat­ed cas­es of metasta­t­ic col­orec­tal can­cer. The study, called ON­SEM­BLE, will en­roll 150 pa­tients, with the pri­ma­ry end­point be­ing the ob­jec­tive re­sponse rate.

The San Diego-based com­pa­ny ex­pects the tri­al to start in Q4 2022, with topline da­ta ex­pect­ed in the sec­ond half of 2024. The com­pa­ny be­lieves that the da­ta may pave the way for ac­cel­er­at­ed ap­proval for the drug in mCRC.

Mean­while, the com­pa­ny al­so shared da­ta from its on­go­ing Phase 1b/II tri­al in KRAS-mu­tat­ed metasta­t­ic col­orec­tal can­cer which showed durable re­spons­es, with a me­di­an du­ra­tion of re­sponse of 11.7 months for all dos­es and 12.5 months for the rec­om­mend­ed Phase II dose.

The com­pa­ny shares $CRDF plum­met­ed 40% on Tues­day.

A lot of com­pa­nies have been ta­per­ing their pipelines as cost-cut­ting mea­sures. Ru­bius Ther­a­peu­tics an­nounced yes­ter­day that it had de­cid­ed to scrap two of its lead­ing pro­grams in sol­id tu­mors.

Cardiff, how­ev­er, said its cash re­serves will fund the com­pa­ny op­er­a­tions in­to 2025.

Forge Bi­o­log­ics’ cGMP Com­pli­ant and Com­mer­cial­ly Vi­able Be­spoke Affin­i­ty Chro­matog­ra­phy Plat­form

Forge Biologics has developed a bespoke affinity chromatography platform approach that factors in unique vector combinations to streamline development timelines and assist our clients in efficiently entering the clinic. By leveraging our experience with natural and novel serotypes and transgene conformations, we are able to accelerate affinity chromatography development by nearly 3-fold. Many downstream purification models are serotype-dependent, demanding unique and time-consuming development strategies for each AAV gene therapy product1. With the increasing demand to propel AAV gene therapies to market, platform purification methods that support commercial-scale manufacturing of high-quality vectors with excellent safety and efficacy profiles are essential.

Who’s spend­ing and who’s cut­ting from Big Phar­ma’s $127B R&D bud­get? Here are the top 15 play­ers

A couple of the Big 15 biopharma companies in R&D hit the gas on research spending last year. Merck and Sanofi still have lots to prove in the pipeline, and they’re willing to gamble large sums to make a better future for themselves.

Doing nothing would be infinitely worse.

But collectively, the top players rang up a modest 2.4% increase in spending in 2022, which didn’t cover inflationary pressures. And that set the tone for an extraordinarily cautious year for the industry — even as it laid out about $127 billion to advance new drugs or up the ante on approved therapies.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jeff Bluestone (R), Sonoma Biotherapeutics CEO

Jef­frey Blue­stone brings his start­up haul to $400M+, join­ing forces with Re­gen­eron on cell ther­a­pies

These days, when Jeffrey Bluestone gets together with his contemporaries in science, the conversation often turns to retirement plans.

But a little more than three years ago, Bluestone reached a momentous turning point in his career, exiting a prestigious post at UCSF, where he had spent decades in the scientific pursuit of new therapies. And it had nothing to do with retirement anytime in the near future.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Mihael Polymeropoulos, Vanda Pharmaceuticals CEO

Van­da wins court case against FDA over dis­clo­sure of CRL de­tails for sleep drug

DC District Court Judge Christopher Cooper today granted Vanda Pharma’s request to require the FDA to disclose more info on the complete response letter for its sleep disorder drug Hetlioz.

The melatonin receptor agonist is approved by the FDA to treat non-24-hour sleep-wake disorder, a circadian rhythm disorder. But in 2018 Vanda filed a supplemental application to market Hetlioz as a treatment for jet lag, which the FDA rejected in August 2019, with few details on what Vanda needed to correct course, according to the company.

Gun­ning for 2023 ap­proval, GSK de­tails PhI­II da­ta for Jem­per­li in front­line en­dome­tri­al can­cer

GSK has a new slate of data to offer on its PD-1 inhibitor, Jemperli — data that the pharma giant hopes will cement one of the four drug approvals it’s expecting this year.

While Jemperli (dostarlimab) is already approved for a subset of patients with second-line endometrial cancer, GSK set out in the Phase III RUBY trial to test it as an earlier line of treatment while also enrolling a broader group of patients. In an interim analysis, Jemperli was shown to extend progression-free survival for both the subset and the overall trial population when added to chemotherapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.

Doug Williams, departing Codiak BioSciences CEO

Co­di­ak files for Chap­ter 11 bank­rupt­cy as most ex­ec­u­tives head for the ex­it

Codiak BioSciences has filed for Chapter 11 bankruptcy, spelling an end to the employment of most executives, including founder Doug Williams, as the biotech says it “expects to consummate a sale.”

The eight-year journey at Codiak is nearing an end with Williams; CFO Linda Bain; medical chief David Mauro; scientific head Sriram Sathyanarayanan; legal and compliance chief Yalonda Howze; and SVP of HR Nicole Barna all packing up their bags in the first few days of April. Chief technology officer Konstantin Konstantinov will stay.

Chaim Lebovits, BrainStorm Cell Therapeutics CEO

Brain­Storm gets FDA ad­comm for ALS drug af­ter failed tri­al and RTF

BrainStorm Cell Therapeutics has had a rocky road trying to get its ALS treatment through to the FDA, including a particularly difficult setback after the FDA slapped the company with a refusal to file (RTF) letter in November after it submitted its original BLA in September last year.

But there’s a glimmer of hope for BrainStorm’s ALS treatment, NurOwn – the FDA will hold an advisory committee meeting to discuss the company’s BLA for the treatment, the company announced today.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.

Sally Susman, Pfizer EVP and chief corporate affairs officer

Q&A: Pfiz­er cor­po­rate com­mu­ni­ca­tions chief Sal­ly Sus­man dis­cuss­es book craft­ed in pan­dem­ic and per­son­al lessons

From the political arena to the finance and beauty industries to pharmaceuticals, Pfizer’s Sally Susman has broken barriers, stereotypes and conventions. And now the chief communicator is “Breaking Through,” the title of her first book about effective and innovative communications launching today. The full official title is “Breaking Through: Communicating to Open Minds, Move Hearts, and Change the World.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Max Colao, OncoVerity CEO

Tiny mul­ti­omics biotech se­cures for­mer J&J drug, new ex­ecs and new fi­nanc­ing

A new spinout from Belgium’s argenx seeks to give new life to a candidate once in-licensed to J&J.

OncoVerity announced Monday afternoon that it had in-licensed cusatuzumab from argenx. The biotech also appointed two new C-suite executives and secured a $30 million Series A round.

CEO Max Colao joins OncoVerity after working as Aurinia’s commercial chief, and stints at Alexion and Amgen. New CMO Clay Smith has been associate chief of the University of Colorado’s hematology division.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.